Richard Duke, PhD, MS

Publications

• Benam CH, Baler G, Duke R, McNeal DM, Muller KA, Bodine C, Morrato EH, Sokol RJ. Fostering innovation at Academic Medical Centers: The Case of University of Colorado Anschutz Medical Campus. J Clin Transl Sci. 2021;5(1):e148. PubMed PMID: 34527288
• Inflammation, Apoptosis, and Necrosis Induced by Neoadjuvant Fas Ligand Gene Therapy Improves Survival of Dogs With Spontaneous Bone Cancer. 2012. Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart EJ, Wilke VL, Charles JB, Munson S, Scott MC, Pozniak J, Carlson CS, Schaack JB and Duke RC. Mol. Ther. 20: 2234-2243.
• Duke RC, Franzusoff A and Apelian D. 2010. T-cell-mediated immunity and immunotherapy of chronic hepatitis C. In press.
• Bui MR, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, Oakes S, Duke R, Apelian D, Franzusoff A, DeGregori J. 2010. Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine 23:6028-35.
• Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC. 2007. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 25:1452-63.
• Everson GT, Tomg MJ, Jacobson IM, Jensen DM, Haller AA, Lauer GM, Parker J, Ferraro J, Cruickshank SE, Duke RC, Apelian D, Rodell TC and Schiff ER. 2006. Interim results from a randomized, double-blind, placebo-controlled phase 1B study in subjects with chronic HCV after treatment with a GI-5005, a yeast-based HCV immunotherapy targeting NS3 and Core proteins. AASLD, Boston MA
• Haller A, King T, Duke R, Mann D, Oakes S, Apelian D, and Franzusoff A. 2006. Targeting influenza with yeast-based tarmogen immnotherapy. Keystone Symposia: Advances in Influenza Research, Steamboat.
• Modiano JF, Breen M, Lana SE, Ehrhart N, Fosmire SP, Thomas R, Jubala CM, Lamerato-Kozicki AR, Ehrhart EJ, Schaack J, Duke RC, Cutter GC, and Bellgrau D. 2006. Naturally occurring translational models for development of cancer gene therapy. Gene Ther. Mol. Biol. 10:31.
• Franzsusoff, A., Duke, R.C., King, T.H., Lu, Y. and Rodell, T.C. 2005. Yeasts encoding tumor antigens in cancer immunotherapy. Expert Opin. Biol. Ther. 5:565-575.